PRKD3 and cardiovascular disorder: Based on the abovementioned facts, it seems that the tissue-specific disruption of Hsp90–PKD3 complex by pharmacological agents might be a potential therapeutic approach not only in tumors, but in other metabolic and cardiovascular diseases.